Prospective Multicenter Evaluation of [ 11 C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease
Journal of Nuclear Medicine · 2025-10 · 66 (10) · 1575-1580
DOI: 10.2967/jnumed.124.269392 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 21.08.2025. Verfasst von Anthime Flaus und 24 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Department, Hospices Civils de Lyon, Lyon, France; anthime.flaus@chu-lyon.fr. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Pituitary ACTH Hypersecretion, Positron-Emission Tomography, Methionine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Functional small pituitary neuroendocrine tumors (PitNETs) of the corticotroph type lead to Cushing disease (CD), a condition associated with significant morbidity and increased mortality. Pituitary MRI is the primary imaging modality used to localize the tumor, but it is inconclusive in up to 30% of cases. Accumulating retrospective evidence suggests that [11C]methionine ([11C]MET) PET could address this diagnostic gap. This prospective study evaluates the sensitivity of [11C]MET PET/MRI compared with MRI for small PitNET localization in CD.
Methods
This prospective multicenter study (ClinicalTrials.gov NCT03346954) included consecutive patients with biochemically confirmed de novo CD who underwent [11C]MET PET/MRI before surgery. Images were evaluated by experienced radiologists and nuclear medicine physicians. Their sensitivity to correctly localized PitNETs was calculated, with pathologic analysis of the surgical specimen used as a reference.
Results
Thirty patients (73% women; mean age, 39.4 ± 12.7 y) underwent PET/MRI, and pathology confirmed PitNET in 22 patients (73%). [11C]MET PET/MRI correctly localized the tumor in 18 patients (82%; 95% CI, 0.60-0.95), whereas MRI correctly localized the tumor in 19 patients (86%; 95% CI, 0.65-0.97; P = 1.0). [11C]MET PET/MRI and MRI were concordant in 18 patients (82%), with the tumor correctly localized in 17 of 18 patients (94%). Among the 4 patients with discordant findings, MRI correctly localized the tumor in 2 cases for which PET was inaccurate; in 1 case, PET accurately identified the lesion, which was not visualized on MRI, and in the final case, both modalities failed to localize the tumor.
Conclusion
This prospective study shows that [11C]MET PET/MRI has high sensitivity but does not differ significantly from 3-T MRI for the accurate localization of small PitNETs of the corticotroph type in patients with de novo CD. Future research could benefit from emerging imaging technologies and should focus on optimizing PET imaging protocols and exploring alternative radiotracers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Department, Hospices Civils de Lyon, Lyon, France; anthime.flaus@chu-lyon.fr.
- Lyon Neuroscience Research Center, CNRS UMR5292, INSERM, U1028, Université Claude Bernard Lyon 1, Lyon, France.
- Radiopharmacy Department, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron, France.
- Research on Healthcare Performance, INSERM, Université Claude Bernard Lyon 1, Lyon, France.
- Pôle de Santé Publique, Service de Recherche et d'Épidémiologie Cliniques, Hospices Civils de Lyon, Lyon, France.
- Department of Endocrinology, Reference Center for Rare Pituitary Diseases, Angers University Hospital, Angers, France.
Zitieren
APA
Flaus, A., Levigoureux, E., Haesebaert, J., Briet, C., Castinetti, F., Cristante, J., Drui, D., Germain, N., Maione, L., Illouz, F., Sonnet, E., Tauveron, I., Merida, I., Lancelot, S., Costes, N., Vasiljevic, A., Marchand, L., Rode, S., Bertholon-Gregoire, M., …, & Raverot, G. (2025). Prospective Multicenter Evaluation of [ 11 C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease. Journal of Nuclear Medicine, 66(10), 1575-1580. https://doi.org/10.2967/jnumed.124.269392
Vancouver
Flaus A, Levigoureux E, Haesebaert J, Briet C, Castinetti F, Cristante J, et al. Prospective Multicenter Evaluation of [ 11 C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease. Journal of Nuclear Medicine. 2025;66(10):1575-1580. doi:10.2967/jnumed.124.269392
BibTeX
@article{Flaus2025,
author = {Flaus, Anthime and Levigoureux, Elise and Haesebaert, Julie and Briet, Claire and Castinetti, Frederic and Cristante, Justine and Drui, Delphine and Germain, Natacha and Maione, Luigi and Illouz, Frederic and Sonnet, Emmanuel and Tauveron, Igor and Merida, Ines and Lancelot, Sophie and Costes, Nicolas and Vasiljevic, Alexandre and Marchand, Lucien and Rode, Sylvie and Bertholon-Gregoire, Mireille and Criton, Guillaume and Lapras, Véronique and Cotton, François and Jouanneau, Emmanuel and Bournaud, Claire and Raverot, Gerald},
title = {Prospective Multicenter Evaluation of [ 11 C]Methionine PET/MRI Sensitivity Compared with MRI for Localizing Small Pituitary Neuroendocrine Tumor or Pituitary Adenoma in Cushing Disease},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {10},
pages = {1575--1580},
doi = {10.2967/jnumed.124.269392}
}
EUVIMED